Literature DB >> 22999943

Autoimmune manifestations in large granular lymphocyte leukemia.

Bruno Bockorny1, Constantin A Dasanu.   

Abstract

Large granular lymphocyte (LGL) leukemia features a group of indolent lymphoproliferative diseases that display a strong association with various autoimmune conditions. Notwithstanding, these autoimmune conditions have not been comprehensively characterized or systematized to date. As a result, their clinical implications remain largely unknown. The authors offer a comprehensive review of the existing literature on various autoimmune conditions documented in the course of T-cell LGL (T-LGL) leukemia. Though some of them are thought be secondary to the LGL leukemia, others could be primary and might even play a role in its pathogenesis. A considerable clinico-laboratory overlap between T-LGL leukemia associated with rheumatoid arthritis and Felty's syndrome suggests that they are just different eponyms for the same clinical entity. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22999943     DOI: 10.1016/j.clml.2012.06.006

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  11 in total

1.  Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia.

Authors:  B Bilori; S Thota; M J Clemente; B Patel; A Jerez; M Afable Ii; J P Maciejewski
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528

2.  The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia.

Authors:  Hanna L M Rajala; Thomas Olson; Michael J Clemente; Sonja Lagström; Pekka Ellonen; Tuija Lundan; David E Hamm; Syed Arshi Uz Zaman; Jesus M Lopez Marti; Emma I Andersson; Andres Jerez; Kimmo Porkka; Jaroslaw P Maciejewski; Thomas P Loughran; Satu Mustjoki
Journal:  Haematologica       Date:  2014-10-03       Impact factor: 9.941

3.  Oral cyclophosphamide was effective for Coombs-negative autoimmune hemolytic anemia in CD16+CD56- chronic lymphoproliferative disorder of NK-cells.

Authors:  Nodoka Sekiguchi; Sayaka Nishina; Toru Kawakami; Hitoshi Sakai; Noriko Senoo; Yasushi Senoo; Toshiro Ito; Hiroshi Saito; Hideyuki Nakazawa; Tomonobu Koizumi; Fumihiro Ishida
Journal:  Int J Hematol       Date:  2016-12-27       Impact factor: 2.490

Review 4.  Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia.

Authors:  HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

5.  A screening method with lymphocyte percentage and proportion of granular lymphocytes in the peripheral blood for large granular lymphocyte (LGL) leukemia.

Authors:  Takahiro Tanahashi; Nodoka Sekiguchi; Kazuyuki Matsuda; Akihiro Matsumoto; Toshiro Ito; Hideyuki Nakazawa; Fumihiro Ishida
Journal:  Int J Hematol       Date:  2016-09-29       Impact factor: 2.490

6.  Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report.

Authors:  Cristina Bagacean; Adrian Tempescul; Mariana Patiu; Bogdan Fetica; Horia Bumbea; Mihnea Zdrenghea
Journal:  Onco Targets Ther       Date:  2016-12-19       Impact factor: 4.147

7.  STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features.

Authors:  Noemí Muñoz-García; María Jara-Acevedo; Carolina Caldas; Paloma Bárcena; Antonio López; Noemí Puig; Miguel Alcoceba; Paula Fernández; Neus Villamor; Juan A Flores-Montero; Karoll Gómez; María Angelina Lemes; Jose Carlos Hernández; Iván Álvarez-Twose; Jose Luis Guerra; Marcos González; Alberto Orfao; Julia Almeida
Journal:  Cancers (Basel)       Date:  2020-11-25       Impact factor: 6.639

8.  Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia.

Authors:  Jani Huuhtanen; Dipabarna Bhattacharya; Tapio Lönnberg; Matti Kankainen; Cassandra Kerr; Jason Theodoropoulos; Hanna Rajala; Carmelo Gurnari; Tiina Kasanen; Till Braun; Antonella Teramo; Renato Zambello; Marco Herling; Fumihiro Ishida; Toru Kawakami; Marko Salmi; Thomas Loughran; Jaroslaw P Maciejewski; Harri Lähdesmäki; Tiina Kelkka; Satu Mustjoki
Journal:  Nat Commun       Date:  2022-04-11       Impact factor: 17.694

Review 9.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

10.  Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients.

Authors:  S Garelli; M Dalla Costa; C Sabbadin; S Barollo; B Rubin; R Scarpa; S Masiero; A Fierabracci; C Bizzarri; A Crinò; M Cappa; M Valenzise; A Meloni; A M De Bellis; C Giordano; F Presotto; R Perniola; D Capalbo; M C Salerno; A Stigliano; G Radetti; V Camozzi; N A Greggio; F Bogazzi; I Chiodini; U Pagotto; S K Black; S Chen; B Rees Smith; J Furmaniak; G Weber; F Pigliaru; L De Sanctis; C Scaroni; C Betterle
Journal:  J Endocrinol Invest       Date:  2021-05-18       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.